Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06099184 · ClinicalTrials.gov registry record · Phase 2
Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)
A Phase 2 study of Diabetic Macular Edema, sponsored by EyePoint Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 6
- Study locations
NCT06099184 is a Phase 2 study of Diabetic Macular Edema that has completed, run by EyePoint Pharmaceuticals. The registered enrollment target is 27 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT06099184, a Phase 2 study of Diabetic Macular Edema, has completed, sponsored by EyePoint Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 6
- Study locations
Study Summary
A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept
Conditions Studied
Interventions
- DRUG EYP-1901
- DRUG Aflibercept 2Mg/0.05Ml Inj,Oph
Study Locations (6)
Arizona
- EyePoint Investigative Site - Phoenix
Illinois
- EyePoint Investigative Site - Lemont
Maryland
- EyePoint Investigative Site - Hagerstown
Nevada
- EyePoint Investigative Site - Reno
Pennsylvania
- EyePoint Investigative Site - Erie
Virginia
- EyePoint Investigative Site - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2024-01-15 |
| Est. Completion | 2024-10-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06099184
The ClinicalTrials.gov registry entry for NCT06099184 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The listed sponsor is EyePoint Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which EYP-1901 is the first listed.
NCT06099184 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arizona, Illinois, Maryland.
Frequently Asked Questions
What is clinical trial NCT06099184 about?
NCT06099184 is a clinical study titled "Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)". A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept
What is the current status of trial NCT06099184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2024-01-15. Estimated completion is 2024-10-24.
What conditions does trial NCT06099184 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT06099184?
The interventions under investigation include: EYP-1901 (DRUG), Aflibercept 2Mg/0.05Ml Inj,Oph (DRUG).
Who is sponsoring clinical trial NCT06099184?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06099184 being conducted?
This trial has 6 study locations across Arizona, Illinois, Maryland, Nevada, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
RECRUITING · Phase 2
-
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
ACTIVE NOT RECRUITING · Phase 2
-
4D-150 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Tonabersat for DME
ACTIVE NOT RECRUITING · Phase 2
-
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.